SOUTH SAN FRANCISCO, CA--(Marketwire - September 24, 2008) - Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that a Late Breaking oral presentation and a poster presentation, each relating to one of two clinical trials for CK-1827452, were presented at the 2008 Annual Heart Failure Society of America (HFSA) Conference, which is being held September 21-24, 2008 at the Metro Toronto Convention Centre in Toronto, Ontario, Canada. These trials, conducted in stable heart failure patients, are evaluating CK-1827452, a novel cardiac myosin activator being developed for the potential treatment of patients with either acutely decompensated or chronic heart failure.
